CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.

Biotechnology

Health Care

Therapeutics

CeleCor Therapeutics

CeleCor Therapeutics' headquarters in Del Mar, CA, United States

Robert S. Hillman

Peter Finn

Oana Cociorva

Marijo Gleeson

Barry S. Coller

Chris Granger

John Maraganore

Sooin Kwon

Andrew Weisenfeld

Gilles Montalescot

Jesse Dylan

Andreas Ritzi

Michael Levy

Jack Lief

C. Michael Gibson

Martin Gerstel

Rob Stars

Description

People (3)

Jack Lief

Marijo Gleeson

Oana Cociorva

Jobs